Dr. Kate Knobil joins the biotech as it looks to combat a viral infection that can be dangerous to patients with the lung ...

GSK PLC closed 21.47% short of its 52-week high of £18.24, which the company reached on May 16th.

Q1 2025 Earnings Call Transcript April 30, 2025 GSK plc beats earnings expectations. Reported EPS is $1.13, expectations were ...

GSK PLC closed 22.73% below its 52-week high of £18.24, which the company reached on May 16th.

GSK has secured the first regulatory approval for Blenrep since the antibody-drug conjugate’s global market withdrawal in 2022. The U.K.’s Medicines and Healthcare products Regulatory Agency ...

GSK (NYSE:GSK) reported Q1 2025 results on Wednesday, narrowly beating analysts’ estimates as the British drugmaker’s ...

Bearish flow noted in GSK (GSK) Pharma with 3,615 puts trading, or 1.6x expected. Most active are May-25 30 puts and Aug-25 35 puts, with total volume in those strikes near 2,700 contracts.

The reversal from the Advisory Committee on Immunization Practices (ACIP) is a potential boost for GSK and Pfizer. Both companies saw sales of their RSV vaccines for adults tumble last year after ...

(Alliance News) - GSK PLC on Thursday said it has received authorisation from the UK Medicines & Healthcare products Regulatory Agency for Blenrep combinations in the treatment of adults with ...

The recommendation also includes GSK plc’s GSK Arexvy in adults aged 50-59 who are at increased risk for severe RSV disease. This expands on ACIP’s previous vote in June 2024 to recommend RSV ...

GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer. The company has ...